Scanned by

    Norton

    Norton™ Safe Web

    Post JP Morgan Healthcare Conference interview with Proactive Investors

    Post JP Morgan Healthcare Conference interview with Proactive Investors

    04:25 |
    Download Here

    You Might Also Like:

    Meet Garrett Gincley, Vice President of Cell Therapy, External Manufacturing, and Imugene Quality.

    Meet Garrett Gincley, Vice President of Cell Therapy, External Manufacturing, and Imugene Quality.

    0:56 |
    Imugene PD1 Vaxx 1080p

    Imugene PD1 Vaxx 1080p

    4:27 |
    Meet Tilanthi Jayawardena, Imugene’s Translational Sciences Lead for azer-cel.

    Meet Tilanthi Jayawardena, Imugene’s Translational Sciences Lead for azer-cel.

    0:51 |
    Investor webinar: Azer-cel trial update, September 2024

    Investor webinar: Azer-cel trial update, September 2024

    25:35 |
    Imugene’s ASX IMU azer cel CAR T therapy trial shows encouraging results in blood cancer

    Imugene’s ASX IMU azer cel CAR T therapy trial shows encouraging results in blood cancer

    1:43 |
    Imugene Limited (ASX:IMU) Three Complete Responses in Azer-Cel Phase 1b Trial

    Imugene Limited (ASX:IMU) Three Complete Responses in Azer-Cel Phase 1b Trial

    3:51 |
    7 News Australia | Australian company Imugene; saving lives using a cancer eating virus

    7 News Australia | Australian company Imugene; saving lives using a cancer eating virus

    2:18 |
    Imugene's new cancer therapy CD19 (OnCARlytics) considered the 'Holy Grail'

    Imugene's new cancer therapy CD19 (OnCARlytics) considered the 'Holy Grail'

    6:16 |
    Imugene (ASX:IMU) | JMM & éthica Capital Innovation Interview \ May 2024

    Imugene (ASX:IMU) | JMM & éthica Capital Innovation Interview \ May 2024

    5:04 |
    Imugene Limited (ASX: IMU) Emergence 2024: Presentation by Leslie Chong, Managing Director and CEO

    Imugene Limited (ASX: IMU) Emergence 2024: Presentation by Leslie Chong, Managing Director and CEO

    7:40 |
    Imugene's CEO interviewed on ausbiz detailing a clinical trial deal with Merck Germany and Pfizer.

    Imugene's CEO interviewed on ausbiz detailing a clinical trial deal with Merck Germany and Pfizer.

    4:12 |
    Leslie Chong & Dr Yuman Fong speak to JustStocks on latest With onCARlytics & MAST Clinical Trials

    Leslie Chong & Dr Yuman Fong speak to JustStocks on latest With onCARlytics & MAST Clinical Trials

    9:07 |
    Imugene featured on Behind The Scenes with Host Laurence Fishburne.

    Imugene featured on Behind The Scenes with Host Laurence Fishburne.

    5:15 |
    Imugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 million

    Imugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 million

    5:34 |
    Imugene opens enrolment for Bile Tract Cancer expansion study

    Imugene opens enrolment for Bile Tract Cancer expansion study

    5:02 |
    'The Why' | Imugene, Developing Cancer Immunotherapies ASX: IMU

    'The Why' | Imugene, Developing Cancer Immunotherapies ASX: IMU

    4:51 |
    Investor webinar – Imugene Limited (ASX:IMU) & Kincell Bio Strategic Partnership Investor Webinar

    Investor webinar – Imugene Limited (ASX:IMU) & Kincell Bio Strategic Partnership Investor Webinar

    18:05 |
    Imugene reports promising results in Phase 1b trial for azer-cel in DLBCL

    Imugene reports promising results in Phase 1b trial for azer-cel in DLBCL

    4:54 |
    Just the Facts: Imugene receives Orphan Drug Designation for VAXINIA from FDA

    Just the Facts: Imugene receives Orphan Drug Designation for VAXINIA from FDA

    1:58 |
    First Patient dosed in Imugene's PD1-Vaxx Combination Trial

    First Patient dosed in Imugene's PD1-Vaxx Combination Trial

    4:00 |